Gissette Reyes-Soffer

List of Publications by Year
in descending order

30	1,372	471509 17	501196 28
papers	citations	h-index	g-index

31	31	31	1474
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated RiskÂofÂCardiovascular Disease and AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 177-192.	2.8	337
2	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATV0000000000000147.	2.4	207
3	Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation, 2017, 135, 352-362.	1.6	185
4	CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1770-1775.	2.4	71
5	The metabolism of lipoprotein (a): an ever-evolving story. Journal of Lipid Research, 2017, 58, 1756-1764.	4.2	67
6	Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. Journal of Clinical Investigation, 2015, 125, 2510-2522.	8.2	67
7	Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. Diabetes Care, 2013, 36, 422-428.	8.6	43
8	Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. Journal of Lipid Research, 2018, 59, 2397-2402.	4.2	43
9	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 7.	2.9	42
10	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 994-1002.	2.4	32
11	Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2013, 27, 1294-1302.	1.5	31
12	Practical Immunoaffinity-Enrichment LC-MS for Measuring Protein Kinetics of Low-Abundance Proteins. Clinical Chemistry, 2014, 60, 1217-1224.	3.2	31
13	Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. Pharmacological Research, 2021, 169, 105689.	7.1	29
14	Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. Science Translational Medicine, 2016, 8, 323ra12.	12.4	27
15	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Molecular and Cellular Proteomics, 2016, 15, 1083-1093.	3.8	23
16	Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2010, 59, 1365-1371.	3.4	20
17	Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. Journal of Lipid Research, 2009, 50, 1901-1909.	4.2	18
18	Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. Journal of Lipid Research, 2017, 58, 1214-1220.	4.2	18

#	Article	IF	Citations
19	Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS. Journal of Lipid Research, 2014, 55, 1179-1187.	4.2	17
20	Autophagy and cardiometabolic risk factors. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 307-315.	5.7	17
21	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2011, 12, 1429-1438.	1.8	16
22	Obesity is independently associated with septic shock, renal complications, and mortality in a multiracial patient cohort hospitalized with COVID-19. PLoS ONE, 2021, 16, e0255811.	2.5	8
23	Relationship Between Body Composition and Death in Patients with COVID-19 Differs Based on the Presence of Gastrointestinal Symptoms. Digestive Diseases and Sciences, 2022, 67, 4484-4491.	2.3	7
24	Life is complicated: so is apoCIII. Journal of Lipid Research, 2019, 60, 1347-1349.	4.2	6
25	Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?. Journal of Clinical Investigation, 2019, 129, 4074-4076.	8.2	5
26	Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 85-89.	2.3	3
27	Abstract 18390: Effects of a Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Healthy Subjects. Circulation, 2015, 132, .	1.6	1
28	Abstract 634: Treatment with Mipomersen Reduces Levels of ApoB-Containing Lipoproteins by Increasing Fractional Removal of VLDL and LDL-apoB Without Reducing VLDL-apob Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	1
29	Abstract 129: Effects of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Normal Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
30	Abstract 120: Effects of Anacetrapib Treatment on CETP Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0